Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Steve King: Just to expand on that a little bit, our stated goal has been ex-U.S. partnering, to primarily keep as much of the U.S. rights as we can, and that remains intact. The reason obviously at this point of partnering is to allow us to expand what we are doing with bavituximab program. We’ve obviously got a number of new clinical studies we’ve identified as being important to start over the coming months, in order so that we can have the data from those studies by the time we unblind the SUNRISE study, but also to be able to run addl. studies in other combinations and other indications, because clearly that’s where the value of the program can be driven upward is through addl. indications and utilization of bavituximab across many different treatment paradigms.
BIO That is significant
Rahul Jasuja - Noble Life Science Partners
And also the other question sort of stems from the fact that there is much said about connecting adapt -- innate immunity and there is a bunch of NK cell [ph] strategies in play as well. From the cytokine profile and looking at the translation work that you guys presented at ImVacS in the lung cancer. So you're seeing interferon [indiscernible] and other cytokines that -- and also converting M1 to -- M2 to M1 macrophages. How significant do you think your approach that [indiscernible] does that, but no other checkpoint inhibitor does that. Any color on that aspect when you could be connecting both the arms of the immune system have and deciding which tumors you're going to attack and how the combination approaches may pan out?
Steven W. King - President and CEO
Yeah I mean I think you've made a great point because what we're doing to this activating events in starting this immune response is basically taking away that natural defense the tumor has for stopping all immune responses, so that's both a native and adaptive killing of the tumor. And so we're really basically reversing that probably equally on both sides of the equation and we have good data that supports that.
CB
You left out the part profitable and with a back log of new business on the books
Avid is a low margin, small, mfg/ business being funded by high risk/return atm capital. Yes it makes sense in getting bavi trialed, approved and to market (should that happen). It is not worth much as a stand-alone business; particularly when considering all the capital pphm has burned through.
The Financial Industry Regulatory Authority slapped their wrist essentially while they made millions in their naked short selling schemes.
As you say the cost of doing business.
BIO Yes there is progress. Will it over shadow the dilution in time?
I think so.
Plus Avid
Peregrine owns the IP 100% of PS Targeting.
Now Memorial Sloan Kettering wants PS Targeting
Now AstraZeneca wants PS Targeting
Bristol Myers Squibb even wanted PS Targeting (for free it seems lol) and yet they still collaborate.
Who is up next ? maybe we get some more hints and puzzle pieces soon
Nice link nothing like this going on here?
Now for something else to consider. Some, maybe all, of us have wondered how there can be such a disparity between share price and our perceived value(where the share price SHOULD be). The following article perhaps provides more than a clue how the share price is being controlled, here and in many other small cap biotechs[from the OCAT and ICell boards]:
http://smithonstocks.com/illegal-naked-short-selling-appears-to-lie-at-the-heart-of-an-extensive-stock-manipulation-scheme/
There is far more than the above title suggests. See if the MOA sounds familiar, and also provides a rationale as to unaccountably "missing shares."
How about the CA anyword on this one yet?
CP
Silver lining in every cloud. More data to be continued.
Paul J. Lytle - CFO
Yes, so I think in general as part of the AZ collaboration of course they are providing the drug itself, which is a huge cost benefit in this sort of trial because it allows us number one full flexibility to start study as quickly as we can, but also that it takes the need to purchase any of the PD-1, PD-L1 inhibitors off the table. So that's a significant benefit for their participation in the current collaboration. And again I think for us one of the key drivers was the ability to get these studies started as soon as we can because our bigger goal here is to be able to generate data again by the time that we unblind the SUNRISE study.
I sold a bunch around 2.79 missed the initial run.
He is buying and selling to increase his shares. He has a knack for it reading the charts.
Agreed
I am not going to make any conclusions yet but let it sink in. Don't know what exactly to think of this.
My son filled his shares at 1.17
However we know that is subject to change given SUNRISE approval.
I share your enthusiasm. EOM
Semper Thanks for informational post.
You own shares you have already drank the cool aid. GLTU
A lifetime friend of my wife's sister had breast cancer about three years ago and it appeared to go into complete remission, just found out the other day that the cancer has come back with a vengeance and has spread to her liver and other parts of her body. Her doctor has given her around 6 months to live. It is a sobering thought to realize while we invest in the potential success of bavi to help the battle against cancer the scope of task to eradicate it.
Paul,
This could not be emphasized any better.
Hypi, gambling that nothing significant will happen in six months could be expensive. Three years ago Peregrine almost inked a partnership, and no one knew about until it came out during the discovery process in the CSM law suit much later.
With MSK and Astrazeneca working with Peregrine and a Phase III trial nearing complete enrolment, Peregrine is a much more attractive partner than it was in 2012. So, something big could happen at any time.
We'll see.
GLTA, Especially Bavi-arm Sunrise Patients,
Paul
Chris looking forward to new article. I read the first article several times over what can I say. Another one please. Thanks.
That would be a 10 bagger for Couch so he would be happy to
Add the dimension of Bavi with the new immunotherapies and I can see Peregrine shares reaching $5-10 by the end of 2016. As my cost average is around 1.30, that would make me very happy.
BRAVO BRAVO Black Tea Party (BIG Pharma) at the front door ready to knock? SK is looking through the peep hole but does he have is hand on the door knob? Or has the tea party already began just waiting on a few more good ole tea bags to wrap it all up. A little theory 101 to contemplate.
BTW your post has been tweeted out a few minutes ago
The current PPHM pipeline is a real headsUP for investors IMO.
Yes fair article from Motley Fool
Chris thanks for update. Looking forward to reading it.
BIO/Couch
If I understand this the way I think I do after all the reading and webinars on PS and bavi SUNRISE should be a resounding success well above Phase 2 results.
Quote:
And Bavi Phase II did not fail- if was successful even with botched data- allowing for phase 3 to commence.
Couch, you are correct! Even after sabotage, Peregrine recovered and salvaged the data and it still was significantly better = 60%.
I think we all wonder how good the data was if it was not tainted with and sabotaged. 200% or better is my guess
Chris we have enough meat in the potatoes for another article for sure.
edcpf That is about where I envision it one year after approval.
Being optimistic. Thanks for for your thoughts
realist1 I agree with lower statement in Italics. Bavi needs a more robust immune system to be more effect EGOG 0 & EGOG 1 patients would provide a more effect treatment protocol.
RE "Pancreatic may not prove anything about the outcome of Sunrise, but it does clearly show that bavi is not a miracle drug that will dramatically help ALL cancers."
I believe that the problem (much as was the case with early phase 1's) is not the type of caner ( in this case pancreatic) but rather the degree of the patients compromised immune system. Bavi has to have something to work with.
Current Institutional Ownership 17.34%
Total Institutional Shares 34,917,899
Institutions 96
Thinking ahead in optimistic mode. Where do you see these numbers
generally one year AFTER Sunrise approval? Anybody care to
throw out some figures.
Lem RS #1 was when they were TCLN in 1983 Right?
Exactly. After reverse split #2 in 2009, they did not adjust the authorized shares accordingly.
CP No need for a lengthy explanation especially to me, I do not expect or deserve one. if a nerve was struck on this subject because I am in your camp. Understand the process enough to know that messaging your shares to increase your long holdings in this manner makes sense. I think the commentary made concerning this was somewhat lighthearted and more in jest. Your too valuable to the board with all your informative posting to be a wolf in sheep's clothing. Please keep up the excellent posting!
I think you will latch on to the caboose before it leaves the station to ride the gravy train a little farther down the track.
CFU I like your math better.
.....what if we only issue 175M OS as the proxy states - issuing a total of 505M OS
and reach a potential 10B market cap vs partnering and keeping OS at 325M but only reaching a 5B market cap since the partner took 50%
5000/325 = $15.38 with partner vs 10000/505 = $19.80 without a partner
hilarious. Wook why you hanging out all day on your PC? Nice day to sell some homes in Philly. Or are you retired and walking around the house in your wookie get up.
Now if we could get dew to say he was wrong(I do understand how he could say placebo about 10 yrs ago though) CP to never short again(at least don't announce) and bid to get over it.....we'll all be singing KoomByaaaa
ECG So are a lot of other folks I am thinking.
I am speculating that there is a common thread ....possibly through MSK/BMY/PPHM/AZN.
I'll be thinking about you when I get off the train at $20 a SH.
My predication which others share in one form or another.
Time lines will very for many here. Yes some have doubts about Bavi approval but....not me!
Interim 1 & 2 look-ins very positive generating approval process
by or before end of 1st QTY 2016?
Resulting in.
by or before end of 3rd QTY
BLA completion process
SUNRISE FDA approval
Several Partnerships EX_US announced
US partnership?
Roll out of several additional collaborations.
by beginning of 4th QTY 2016
More contracts awarded for Avid & commercial production of Bavi
How the 175 mil factors into the events unfolding above I leave that for someone else to opine on.
IMO
Sep 6–9, 2015 IASLC World Conference on Lung Cancer (WCLC 2015)
Denver, CO
Visit Peregrine at booth # 1724
Gee whats another 25 mil
CP this advantage would facilitate the trail and expedite results saving time which is of the essence
Agreed...
So I would see AZ contribute in that domain, using its Med. Reps that are already in place, rather then see them give cash to PPHM. Personally I prefer that over cash because PPHM can impossibly achieve that same result even with high amounts of cash. You need to know where the Durvalumab patients are and AZ know where they deliver the drug and what Doctors are their big prescribers.